Evidence map›Paper›PMID 29972332›Full record

ArticlePulmonary circulation

The efficacy and safety of pulmonary vasodilators in patients with Fontan circulation: a meta-analysis of randomized controlled trials.

Wuwan Wang, Xiankang Hu, Weitin Liao, W H Rutahoile, David J Malenka, Xiaofang Zeng, Yunjing Yang, Panpan Feng, Li Wen, Wei Huang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pulmonary circulation. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Cardiac Drugs in ACHD Cardiovascular Medicine.Journal of cardiovascular development and disease · 2023
    Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Wuwan Wang1 Department of Cardiology, the First Affiliated Hospital, Chongqing Medical University, Chongqing, China.
Xiankang Hu2 Chongqing Medical University, Chongqing, China.
Weitin Liao2 Chongqing Medical University, Chongqing, China.
W H Rutahoile1 Department of Cardiology, the First Affiliated Hospital, Chongqing Medical University, Chongqing, China.
David J Malenka3 Section of Cardiovascular Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, USA.
Xiaofang Zeng1 Department of Cardiology, the First Affiliated Hospital, Chongqing Medical University, Chongqing, China.
Yunjing Yang1 Department of Cardiology, the First Affiliated Hospital, Chongqing Medical University, Chongqing, China.
Panpan Feng1 Department of Cardiology, the First Affiliated Hospital, Chongqing Medical University, Chongqing, China.
Li Wen1 Department of Cardiology, the First Affiliated Hospital, Chongqing Medical University, Chongqing, China.
Wei Huang1 Department of Cardiology, the First Affiliated Hospital, Chongqing Medical University, Chongqing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

No previous meta-analysis has evaluated the efficacy and safety of pulmonary vasodilators in Fontan physiology. Recent relative trials have obtained conflicting results regarding improvements in peak oxygen consumption; the relatively small number of patients in each study may be a limiting factor. We aimed to evaluate the efficacy and safety of pulmonary vasodilators in Fontan patients. Relevant studies were identified by searching the PubMed, Embase, and Cochrane Library databases. Pooled outcomes were determined to assess the efficacy and safety of pulmonary vasodilators in Fontan patients. Nine randomized controlled studies involving 381 patients with Fontan circulation were included. Pulmonary vasodilator therapy led to significant improvement (mean difference = -0.39, 95% CI: [-0.72, -0.05]) in the New York Heart Association (NYHA) functional class. The 6-minute walking distance (6MWD) was significantly increased by 134 m (95% CI: [86.07, 181.94]), and the peak VO

Indexed as

endothelin-1 receptor antagonistFontan procedureoutcomesPDE-5 inhibitor

Identifiers

PMID29972332
PMCPMC6348526

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.